ChemoCentryx's Total Assets for the quarter that ended in Jun. 2022 was $419.39 Mil.
Warning Sign:
If a company builds assets at 32.3% a year, faster than its revenue growth rate of 3.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, ChemoCentryx's average Total Assets Growth Rate was -41.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 194.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 32.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 18.80% per year.
During the past 13 years, ChemoCentryx's highest 3-Year average Total Assets Growth Rate was 194.20%. The lowest was -29.50%. And the median was 7.40%.
The historical data trend for ChemoCentryx's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
ChemoCentryx's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Jun. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
ChemoCentryx's Asset Turnover for the quarter that ended in Jun. 2022 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
ChemoCentryx Total Assets Related Terms
Thank you for viewing the detailed overview of ChemoCentryx's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CCXI has been successfully added to your 